Could safety scupper Ionis, Pfizer’s cholesterol drug vupanorsen?Ionis has reported phase 2b trial data for its Pfizer-partnered antisense drug vupanorsen for cholesterol lowering that showed Share XCould safety scupper Ionis, Pfizer’s cholesterol drug vupanorsen?https://pharmaphorum.com/news/could-safety-scupper-ionis-pfizers-cholesterol-drug-vupanorsen/
Vaccibody rebrands as Nykode, and unveils big Regeneron partnershipNorwegian biotech Vaccibody has changed its name to Nykode Therapeutics, and celebrated its new identity with a sizeable Share XVaccibody rebrands as Nykode, and unveils big Regeneron partnershiphttps://pharmaphorum.com/news/vaccibody-rebrands-as-nykode-and-unveils-big-regeneron-partnership/
Merck’s oral PCSK9 drug matches injectables in early trialsInjectable antibodies targeting PCSK9 have failed to take off as expected in the cholesterol-lowering market, but Merck & Share XMerck’s oral PCSK9 drug matches injectables in early trialshttps://pharmaphorum.com/news/mercks-oral-pcsk9-drug-matches-injectables-in-early-trials/
COVID antibodies from Roche, Celltrion backed for approval in EUThe EMA’s human medicines committee has recommended approval of Roche’s Ronapreve and Celltrion’s Regkirona for use in COVID-19, Share XCOVID antibodies from Roche, Celltrion backed for approval in EUhttps://pharmaphorum.com/news/first-covid-antibodies-from-roche-celltrion-backed-in-eu/
One dose of Regeneron’s COVID antibody protects for eight monthsA single dose of the COVID-19 monoclonal antibody therapy developing Regeneron reduced the risk of contracting the virus Share XOne dose of Regeneron’s COVID antibody protects for eight monthshttps://pharmaphorum.com/news/one-dose-of-regenerons-covid-antibody-protects-for-eight-months/
FDA clears Roche’s Susvimo implant for eye disease wet AMDRoche’s Genentech unit has won FDA approval for Susvimo, an implant for eyesight-robbing disease wet age-related macular degeneration Share XFDA clears Roche’s Susvimo implant for eye disease wet AMDhttps://pharmaphorum.com/news/fda-clears-roches-susvimo-implant-for-eye-disease-wet-amd/
Dupixent scores a first in rare skin disease prurigo nodularisSanofi and Regeneron’s Dupixent has become the first biologic drug to show activity in prurigo nodularis (PN), raising Share XDupixent scores a first in rare skin disease prurigo nodularishttps://pharmaphorum.com/news/dupixent-scores-a-first-in-rare-skin-disease-prurigo-nodularis/
NICE changes stance on Sanofi’s Dupixent for severe asthma18 months after saying “no” to regular NHS funding for Sanofi and Regeneron’s Dupixent (dupilumab) for severe asthma Share XNICE changes stance on Sanofi’s Dupixent for severe asthmahttps://pharmaphorum.com/news/nice-changes-stance-on-sanofis-dupixent-for-severe-asthma/
ESMO21: Libtayo extends survival in first-line NSCLC, challenging KeytrudaThere’s no shortage of cancer immunotherapies trying to knock Merck & Co’s Keytruda off the top of the Share XESMO21: Libtayo extends survival in first-line NSCLC, challenging Keytrudahttps://pharmaphorum.com/news/esmo21-libtayo-extends-survival-in-first-line-nsclc-challenging-keytruda/
